Sponsor content
268 result(s) found, displaying 11 to 20
-
Sep-2025Prescription medicine evaluationActive ingredient: ibrutinib.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAZCLUZE lazertinib 240 mg film-coated tablets bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAZCLUZE lazertinib 240 mg film-coated tablets blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAZCLUZE lazertinib 80 mg film-coated tablets bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAZCLUZE lazertinib 80 mg film-coated tablets blister pack.
-
-
Australian public assessment report (AusPar)TALVEY (talquetamab) has been provisionally approved for the treatment of adult patients with relapsed or refractory multiple myeloma.
-
Prescription medicine registrationActive ingredients: daratumumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DARZALEX daratumumab 100 mg/5 mL concentrated solution for infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DARZALEX daratumumab 400 mg/20 mL concentrated solution for infusion vial.